Impact of Filtration on Autologous Serum Eye Drops (NCT07407101) | Clinical Trial Compass
CompletedNot Applicable
Impact of Filtration on Autologous Serum Eye Drops
France10 participantsStarted 2026-04-13
Plain-language summary
Dry eye disease accounts for nearly 25% of ophthalmology consultations, making it a commonly encountered condition. When conventional treatments fail autologous serum in the form of eye drops, have been proposed as a therapeutic option. With the aim of standardizing the preparation of autologous serum eye drops in France, the main objective is to describe the absolute and relative differences (before and after filtration) in the concentrations of active molecules in the autologous serum of patients suffering from severe dry eye disease.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* adult patients
* patients covered by health insurance
* patients managed by the Ophtalmology Department of the University Hospital of Limoges
* patients diagnosed with dry eyes syndrome, who have not responded to conventionnal treatments
* free, informed, written and signed consent
Exclusion Criteria:
* person incapable of consent
* legal guardianship or wardship
* patient who does not wish to know the results of serological tests
Secondary exclusion criteria:
\- a positive serology for at least of of the following agents (HIV, HCV, HBV or syphilis)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial looked at how filtration affects the concentrations of active molecules in autologous serum eye drops for dry eye syndrome — can you explain what autologous serum eye drops are, and whether the filtration method used in this completed study might matter if I were ever prescribed them?
2Since this trial is listed as phase 'NA' and focused on measuring differences in active molecule concentrations rather than patient outcomes, does that mean we don't yet have direct evidence about how these findings translate to symptom relief for people with dry eye syndrome?
3Now that this trial is completed, have the results been published anywhere, and would they change how you might prepare or recommend autologous serum eye drops for someone with my level of dry eye?
4Are autologous serum eye drops something you'd consider for my situation, and if so, does the filtration process your clinic uses align with what was studied in this trial?
5If autologous serum eye drops aren't right for me yet, what standard dry eye treatments would you recommend trying first while this kind of research continues to develop?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.